Buy Or Sell Opportunity • Jun 04
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 19% to CN¥23.89. The fair value is estimated to be CN¥30.13, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 4.9% over the last 3 years. Earnings per share has declined by 7.9%. Revenue is forecast to grow by 29% in 2 years. Earnings are forecast to grow by 54% in the next 2 years. Reported Earnings • May 01
First quarter 2026 earnings released: EPS: CN¥0.11 (vs CN¥0.13 in 1Q 2025) First quarter 2026 results: EPS: CN¥0.11 (down from CN¥0.13 in 1Q 2025). Revenue: CN¥296.3m (up 2.1% from 1Q 2025). Net income: CN¥44.2m (down 15% from 1Q 2025). Profit margin: 15% (down from 18% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings. Announcement • Mar 30
Shandong Weigao Orthopaedic Device Co., Ltd to Report Q1, 2026 Results on Apr 30, 2026 Shandong Weigao Orthopaedic Device Co., Ltd announced that they will report Q1, 2026 results on Apr 30, 2026 Announcement • Mar 28
Shandong Weigao Orthopaedic Device Co., Ltd, Annual General Meeting, May 28, 2026 Shandong Weigao Orthopaedic Device Co., Ltd, Annual General Meeting, May 28, 2026, at 14:30 China Standard Time. Location: No. 499, Fangting Road, Minhang District, Shanghai China Reported Earnings • Mar 01
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: EPS: CN¥0.67 (up from CN¥0.56 in FY 2024). Revenue: CN¥1.54b (up 6.0% from FY 2024). Net income: CN¥266.6m (up 19% from FY 2024). Profit margin: 17% (up from 15% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.5%. Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings. Buy Or Sell Opportunity • Jan 13
Now 20% overvalued The stock has been flat over the last 90 days, currently trading at CN¥30.95. The fair value is estimated to be CN¥25.75, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 15% over the last 3 years. Earnings per share has declined by 44%. Revenue is forecast to grow by 31% in 2 years. Earnings are forecast to grow by 37% in the next 2 years. Announcement • Dec 26
Shandong Weigao Orthopaedic Device Co., Ltd to Report Fiscal Year 2025 Results on Mar 28, 2026 Shandong Weigao Orthopaedic Device Co., Ltd announced that they will report fiscal year 2025 results on Mar 28, 2026 Board Change • Dec 07
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Hongwei Liu was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Buy Or Sell Opportunity • Nov 14
Now 21% overvalued The stock has been flat over the last 90 days, currently trading at CN¥31.07. The fair value is estimated to be CN¥25.72, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 15% over the last 3 years. Earnings per share has declined by 44%. Revenue is forecast to grow by 37% in 2 years. Earnings are forecast to grow by 35% in the next 2 years. Announcement • Sep 30
Shandong Weigao Orthopaedic Device Co., Ltd to Report Q3, 2025 Results on Oct 31, 2025 Shandong Weigao Orthopaedic Device Co., Ltd announced that they will report Q3, 2025 results on Oct 31, 2025 Valuation Update With 7 Day Price Move • Sep 11
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CN¥35.76, the stock trades at a forward P/E ratio of 51x. Average forward P/E is 27x in the Medical Equipment industry in China. Total loss to shareholders of 34% over the past three years. Announcement • Jun 30
Shandong Weigao Orthopaedic Device Co., Ltd to Report First Half, 2025 Results on Aug 28, 2025 Shandong Weigao Orthopaedic Device Co., Ltd announced that they will report first half, 2025 results on Aug 28, 2025 Reported Earnings • May 05
First quarter 2025 earnings released: EPS: CN¥0.13 (vs CN¥0.09 in 1Q 2024) First quarter 2025 results: EPS: CN¥0.13 (up from CN¥0.09 in 1Q 2024). Revenue: CN¥290.2m (down 17% from 1Q 2024). Net income: CN¥51.8m (up 48% from 1Q 2024). Profit margin: 18% (up from 10.0% in 1Q 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance. New Risk • May 03
New major risk - Revenue and earnings growth Earnings have declined by 37% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company. Announcement • Mar 28
Shandong Weigao Orthopaedic Device Co., Ltd to Report Q1, 2025 Results on Apr 30, 2025 Shandong Weigao Orthopaedic Device Co., Ltd announced that they will report Q1, 2025 results on Apr 30, 2025 Announcement • Mar 27
Shandong Weigao Orthopaedic Device Co., Ltd, Annual General Meeting, Apr 21, 2025 Shandong Weigao Orthopaedic Device Co., Ltd, Annual General Meeting, Apr 21, 2025, at 14:30 China Standard Time. Location: No. 26, Xiangjiang Street, Tourism Resort, Weihai, Shandong China Reported Earnings • Mar 02
Full year 2024 earnings: EPS in line with expectations, revenues disappoint Full year 2024 results: EPS: CN¥0.55 (up from CN¥0.28 in FY 2023). Revenue: CN¥1.45b (up 13% from FY 2023). Net income: CN¥221.8m (up 98% from FY 2023). Profit margin: 15% (up from 8.8% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance. Announcement • Dec 27
Shandong Weigao Orthopaedic Device Co., Ltd to Report Fiscal Year 2024 Results on Mar 27, 2025 Shandong Weigao Orthopaedic Device Co., Ltd announced that they will report fiscal year 2024 results on Mar 27, 2025 Announcement • Dec 18
Shandong Weigao Orthopaedic Device Co., Ltd(SHSE:688161) dropped from Shanghai Stock Exchange Health Care Sector Index Shandong Weigao Orthopaedic Device Co., Ltd has been removed from Shanghai Stock Exchange Health Care Sector Index. Announcement • Sep 30
Shandong Weigao Orthopaedic Device Co., Ltd to Report Q3, 2024 Results on Oct 31, 2024 Shandong Weigao Orthopaedic Device Co., Ltd announced that they will report Q3, 2024 results on Oct 31, 2024 Reported Earnings • Aug 29
Second quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.043 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.14 (up from CN¥0.043 in 2Q 2023). Revenue: CN¥402.6m (down 3.1% from 2Q 2023). Net income: CN¥58.2m (up 231% from 2Q 2023). Profit margin: 14% (up from 4.2% in 2Q 2023). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 31% per year, which means it has not declined as severely as earnings. Announcement • Jun 29
Shandong Weigao Orthopaedic Device Co., Ltd to Report First Half, 2024 Results on Aug 29, 2024 Shandong Weigao Orthopaedic Device Co., Ltd announced that they will report first half, 2024 results on Aug 29, 2024 Reported Earnings • May 01
First quarter 2024 earnings released: EPS: CN¥0.09 (vs CN¥0.24 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.09 (down from CN¥0.24 in 1Q 2023). Revenue: CN¥347.9m (down 11% from 1Q 2023). Net income: CN¥34.9m (down 63% from 1Q 2023). Profit margin: 10.0% (down from 24% in 1Q 2023). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Announcement • Mar 29
Shandong Weigao Orthopaedic Device Co., Ltd to Report Q1, 2024 Results on Apr 30, 2024 Shandong Weigao Orthopaedic Device Co., Ltd announced that they will report Q1, 2024 results on Apr 30, 2024 Announcement • Mar 27
Shandong Weigao Orthopaedic Device Co., Ltd, Annual General Meeting, Apr 29, 2024 Shandong Weigao Orthopaedic Device Co., Ltd, Annual General Meeting, Apr 29, 2024, at 14:50 China Standard Time. Location: The Company's Meeting Room, Weihai, Shandong China Reported Earnings • Feb 29
Full year 2023 earnings released: EPS: CN¥0.28 (vs CN¥1.36 in FY 2022) Full year 2023 results: EPS: CN¥0.28 (down from CN¥1.36 in FY 2022). Revenue: CN¥1.28b (down 31% from FY 2022). Net income: CN¥112.4m (down 79% from FY 2022). Profit margin: 8.8% (down from 29% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 45% p.a. on average during the next 2 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to CN¥28.36, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 19x in the Medical Equipment industry in China. Total loss to shareholders of 58% over the past year. Reported Earnings • Nov 01
Third quarter 2023 earnings released: EPS: CN¥0.027 (vs CN¥0.11 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.027 (down from CN¥0.11 in 3Q 2022). Revenue: CN¥277.1m (down 3.7% from 3Q 2022). Net income: CN¥10.3m (down 77% from 3Q 2022). Profit margin: 3.7% (down from 15% in 3Q 2022). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Reported Earnings • Aug 30
Second quarter 2023 earnings released: EPS: CN¥0.043 (vs CN¥0.76 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.043 (down from CN¥0.76 in 2Q 2022). Revenue: CN¥415.6m (down 46% from 2Q 2022). Net income: CN¥17.6m (down 94% from 2Q 2022). Profit margin: 4.2% (down from 39% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Announcement • Aug 18
Shandong Weigao Orthopaedic Device Co., Ltd (SHSE:688161) announces an Equity Buyback for CNY 120 million worth of its shares. Shandong Weigao Orthopaedic Device Co., Ltd (SHSE:688161) announces a share repurchase program. Under the program, the company will repurchase CNY 120 million worth of its shares. The program will be valid till 12 months. Announcement • Jun 28
Shandong Weigao Orthopaedic Device Co., Ltd to Report First Half, 2023 Results on Aug 30, 2023 Shandong Weigao Orthopaedic Device Co., Ltd announced that they will report first half, 2023 results on Aug 30, 2023 Board Change • Apr 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Director Ruijie Zhang was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Mar 30
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: EPS: CN¥1.36 (down from CN¥1.82 in FY 2021). Revenue: CN¥1.85b (down 14% from FY 2021). Net income: CN¥544.2m (down 21% from FY 2021). Profit margin: 29% (down from 32% in FY 2021). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 28%. Earnings per share (EPS) also missed analyst estimates by 35%. Revenue is forecast to grow 36% p.a. on average during the next 2 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Valuation Update With 7 Day Price Move • Jan 10
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥60.68, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 24x in the Medical Equipment industry in China. Total loss to shareholders of 5.5% over the past year. Reported Earnings • Oct 30
Third quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.31 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.11 (down from CN¥0.31 in 3Q 2021). Revenue: CN¥287.8m (down 39% from 3Q 2021). Net income: CN¥44.3m (down 65% from 3Q 2021). Profit margin: 15% (down from 26% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Medical Equipment industry in China. Valuation Update With 7 Day Price Move • Oct 17
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥70.93, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 26x in the Medical Equipment industry in China. Total returns to shareholders of 1.6% over the past year. Valuation Update With 7 Day Price Move • Sep 29
Investor sentiment improved over the past week After last week's 23% share price gain to CN¥60.60, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 22x in the Medical Equipment industry in China. Total loss to shareholders of 18% over the past year. Reported Earnings • Aug 24
Second quarter 2022 earnings released: EPS: CN¥0.76 (vs CN¥0.65 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.76 (up from CN¥0.65 in 2Q 2021). Revenue: CN¥765.4m (up 14% from 2Q 2021). Net income: CN¥300.1m (up 16% from 2Q 2021). Profit margin: 39% (in line with 2Q 2021). Over the next year, revenue is forecast to grow 38%, compared to a 26% growth forecast for the Medical Equipment industry in China. Buying Opportunity • Aug 19
Now 22% undervalued Over the last 90 days, the stock is up 20%. The fair value is estimated to be CN¥64.14, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.8% over the last year, while earnings per share has been flat. Revenue is forecast to grow by 69% in 2 years. Earnings is forecast to grow by 70% in the next 2 years. Board Change • Aug 14
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Bin Jia was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Aug 02
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥58.78, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 24x in the Medical Equipment industry in China. Total loss to shareholders of 16% over the past year. Buying Opportunity • Jul 22
Now 20% undervalued Over the last 90 days, the stock is up 12%. The fair value is estimated to be CN¥63.94, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.8% over the last year, while earnings per share has been flat. Revenue is forecast to grow by 69% in 2 years. Earnings is forecast to grow by 70% in the next 2 years. Reported Earnings • Apr 29
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: EPS: CN¥0.24 (down from CN¥0.31 in 1Q 2021). Revenue: CN¥339.8m (down 19% from 1Q 2021). Net income: CN¥97.9m (down 12% from 1Q 2021). Profit margin: 29% (up from 26% in 1Q 2021). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 7.8%. Earnings per share (EPS) also missed analyst estimates by 2.2%. Over the next year, revenue is forecast to grow 36%, compared to a 25% growth forecast for the industry in China. Reported Earnings • Mar 30
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: EPS: CN¥1.86 (up from CN¥1.56 in FY 2020). Revenue: CN¥2.15b (up 18% from FY 2020). Net income: CN¥703.7m (up 26% from FY 2020). Profit margin: 33% (up from 31% in FY 2020). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 7.8%. Earnings per share (EPS) also missed analyst estimates by 2.2%. Over the next year, revenue is forecast to grow 38%, compared to a 24% growth forecast for the industry in China. Reported Earnings • Feb 24
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: EPS: CN¥1.86 (up from CN¥1.56 in FY 2020). Revenue: CN¥2.15b (up 18% from FY 2020). Net income: CN¥703.7m (up 26% from FY 2020). Profit margin: 33% (up from 31% in FY 2020). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 7.9%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 38%, compared to a 24% growth forecast for the industry in China. Valuation Update With 7 Day Price Move • Oct 20
Investor sentiment deteriorated over the past week After last week's 15% share price decline to CN¥67.31, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 31x in the Medical Equipment industry in China. Valuation Update With 7 Day Price Move • Sep 14
Investor sentiment improved over the past week After last week's 23% share price gain to CN¥75.21, the stock trades at a trailing P/E ratio of 43.9x. Average trailing P/E is 37x in the Medical Equipment industry in China. 